Alcoholic liver disease: Pathogenesis and new targets for therapy

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 9, 2011, Pages 491-501

  Altamirano, José ^a   Bataller, Ramón ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALPHA TOCOPHEROL; BACLOFEN; CARBOHYDRATE DEFICIENT TRANSFERRIN; COLCHICINE; CORTICOSTEROID; CYTOCHROME P450 2E1; DISULFIRAM; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON; INFLIXIMAB; INSULIN; INTERLEUKIN 17; INTERLEUKIN 22; NALTREXONE; OSTEOPONTIN; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; PROPYLTHIOURACIL; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SILIBININ; STAT PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; VERY LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALCOHOL REHABILITATION PROGRAM; ALCOHOLISM; DISABILITY; DISEASE COURSE; DRUG DOSE REDUCTION; ENTERIC FEEDING; ENVIRONMENTAL FACTOR; FATTY LIVER; HEPATITIS; HEREDITY; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; LIVER NECROSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARENTERAL NUTRITION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN TARGETING; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR;

ANIMALS; CHEMOKINES, CXC; DISEASE MODELS, ANIMAL; HUMANS; LIVER DISEASES, ALCOHOLIC; OSTEOPONTIN; PREVALENCE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 80052433519     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.134     Document Type: Review

References (146)

1. Becker, U. et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 23, 1025-1029 (1996). (Pubitemid 26137041)
2. Tome, S. & Lucey, M. R. Review article: current management of alcoholic liver disease. Aliment. Pharmacol. Ther. 19, 707-714 (2004). (Pubitemid 38496636)
3. Gao, B. et al. Innate immunity in alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G516-G525 (2011).
4. Goodman, Z., Makhlouf, H. & Younossi, Z. Reply. Hepatology 54, 370-371 (2011).
5. Gleeson, D. et al. HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and with normal controls. Am. J. Gastroenterol. 101, 304-310 (2006). (Pubitemid 43381672)
6. Singal, A. K., Sagi, S., Kuo, Y. F. & Weinman, S. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis. Eur. J. Gastroenterol. Hepatol. 23, 204-209 (2011).
7. Gitto, S., Micco, L., Conti, F., Andreone, P. & Bernardi, M. Alcohol and viral hepatitis: a mini-review. Dig. Liver Dis. 41, 67-70 (2009).
8. Clouston, A. D., Jonsson, J. R. & Powell, E. E. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin. Liver Dis. 11, 173-189 (2007). (Pubitemid 46829972)
9. The world health report (2002)-reducing risks, promoting healthy life. World Health Organization [online], http://www.who.int/whr/2002/en/(2002).
10. Cortez-Pinto, H. et al. The burden of disease and the cost of illness attributable to alcohol drinking-results of a national study. Alcohol. Clin. Exp. Res. 34, 1442-1449 (2010).
11. Rehm, J. et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373, 2223-2233 (2009).
12. Paula, H. et al. Alcoholic liver disease-related mortality in the United States: 1980-2003. Am. J. Gastroenterol. 105, 1782-1787 (2010).
13. European liver transplant registry. ELTR.org [online], http://www.eltr.org/spip.php?spip0 (2011).
14. Mackie, J. et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transplant. 7, 418-427 (2001). (Pubitemid 32496144)
15. Transplant fast facts. Arbor Research Collaborative for Health [online], http://www.ustransplant.org (2011).
16. Burra, P. et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry).Am. J. Transplant. 10, 138-148 (2010).
17. Lefkowitch, J. H. Morphology of alcoholic liver disease. Clin. Liver Dis. 9, 37-53 (2005). (Pubitemid 40341945)
18. Elphick, D. A., Dube, A. K., McFarlane, E., Jones, J. & Gleeson, D. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am. J. Gastroenterol. 102, 780-788 (2007). (Pubitemid 46496603)
19. Adachi, M. & Brenner, D. A. Clinical syndromes of alcoholic liver disease. Dig. Dis. 23, 255-263 (2005). (Pubitemid 43325925)
20. Lucey, M. R., Mathurin, P. & Morgan, T. R. Alcoholic hepatitis. N. Engl. J. Med. 360, 2758-2769 (2009).
21. Maddrey, W. C. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75, 193-199 (1978). (Pubitemid 8372264)
22. Dunn, W. et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41, 353-358 (2005). (Pubitemid 40165379)
23. Dominguez, M. et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103, 2747-2756 (2008).
24. Louvet, A. et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 45, 1348-1354 (2007). (Pubitemid 46918318)
25. Forrest, E. H. et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54, 1174-1179 (2005). (Pubitemid 41025916)
26. Bortolotti, F., De Paoli, G. & Tagliaro, F. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 841, 96-109 (2006). (Pubitemid 44279557)
27. Hietala, J. et al. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol. 41, 528-533 (2006). (Pubitemid 44404470)
28. Pessione, F. et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int. 23, 45-53 (2003). (Pubitemid 37265774)
29. Chedid, A. et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am. J. Gastroenterol. 86, 210-216 (1991).
30. Amini, M. & Runyon, B. A. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J. Gastroenterol. 16, 4905-4912 (2010).
31. Addolorato, G. et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol- dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370, 1915-1922 (2007). (Pubitemid 350192657)
32. Palmer, A. J. et al. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol. 35, 478-492 (2000).
33. Garbutt, J. C. et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293, 1617-1625 (2005). (Pubitemid 40471792)
34. Fuller, R. K. & Gordis, E. Does disulfiram have a role in alcoholism treatment today? Addiction 99, 21-24 (2004). (Pubitemid 38142216)
35. Stickel, F., Hoehn, B., Schuppan, D. & Seitz, H. K. Nutritional therapy in alcoholic liver disease. Aliment. Pharmacol. Ther. 18, 357-373 (2003). (Pubitemid 37070234)
36. Mendenhall, C. L. et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N. Engl. J. Med. 311, 1464-1470 (1984). (Pubitemid 15211021)
37. Mezey, E., Potter, J. J., Rennie-Tankersley, L., Caballeria, J. & Pares, A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J. Hepatol. 40, 40-46 (2004). (Pubitemid 38064711)
38. Parés, A. et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicentre trial. J. Hepatol. 28, 615-621 (1998). (Pubitemid 28167999)
39. Rambaldi, A. & Gluud, C. Meta-analysis of propylthiouracil for alcoholic liver disease-a Cochrane Hepato-Biliary Group Review. Liver 21, 398-404 (2001). (Pubitemid 33095043)
40. Akriviadis, E. A. et al. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 99, 811-818 (1990). (Pubitemid 20243375)
41. Trinchet, J. C. et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 15, 76-81 (1992).
42. O'Shea, R. S., Dasarathy, S. & McCullough, A. J. Alcoholic liver disease. Am. J. Gastroenterol. 105, 14-32 (2010).
43. Akriviadis, E. et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119, 1637-1648 (2000). (Pubitemid 32198689)
44. Mathurin, P. et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 60, 255-260 (2011).
45. Naveau, S. et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39, 1390-1397 (2004). (Pubitemid 38569061)
46. Spahr, L. et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J. Hepatol. 37, 448-455 (2002).
47. Tilg, H. et al. Anti-tumor necrosis factor-α monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 38, 419-425 (2003). (Pubitemid 36399243)
48. Menon, K. V. et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am. J. Gastroenterol. 99, 255-260 (2004). (Pubitemid 38279865)
49. O'Shea, R. S., Dasarathy, S. & McCullough, A. J., Practice Guideline Committee of the American Association for the Study of Liver Diseases & Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 51, 307-328 (2010).
50. Salaspuro, M. P., Shaw, S., Jayatilleke, E., Ross, W. A. & Lieber, C. S. Attenuation of the ethanol-induced hepatic redox change after chronic alcohol consumption in baboons: metabolic consequences in vivo and in vitro. Hepatology 1, 33-38 (1981). (Pubitemid 11055586)
51. Sozio, M. S., Liangpunsakul, S. & Crabb, D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin. Liver Dis. 30, 378-390 (2010).
52. Zhou, J. et al. Hepatic fatty acid transporter CD36 is a common target of, LXR, PXR, and PPAR? in promoting steatosis. Gastroenterology 134, 556-567 (2008).
53. Coll, O., Colell, A., Garcia-Ruiz, C., Kaplowitz, N. & Fernández-Checa. J. C. Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology 38, 692-702 (2003). (Pubitemid 37052156)
54. Hoek, J. B., Cahill, A. & Pastorino, J. G. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 122, 2049-2063 (2002). (Pubitemid 34651446)
55. Sozio, M. & Crabb, D. W. Alcohol and lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 295, E10-E16 (2008).
56. Galli, A., Pinaire, J., Fischer, M., Dorris, R. & Crabb, D. W. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor α is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J. Biol. Chem. 276, 68-75 (2001). (Pubitemid 32050290)
57. You, M., Fischer, M., Deeg, M. A. & Crabb, D. W. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP).J. Biol. Chem. 277, 29342-29347 (2002).
58. You, M., Matsumoto, M., Pacold, C. M., Cho, W. K. & Crabb, D. W. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127, 1798-1808 (2004). (Pubitemid 39575858)
59. Sugimoto, T. et al. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J. Hepatol. 36, 157-162 (2002). (Pubitemid 34146421)
60. Bataller, R., Rombouts, K., Altamirano, J. & Marra, F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 25, 231-244 (2011).
61. Tian, C., Stokowski, R. P., Kershenobich, D., Ballinger, D. G. & Hinds, D. A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42, 21-23 (2010).
62. Altamirano, J. et al. The amount of alcohol consumption negatively impacts short-term mortality in patients with alcoholic hepatitis. Am. J. Gastroenterol. doi:10.1038/ajg.2011.141.
63. MacSween, R. N. & Burt, A. D. Histologic spectrum of alcoholic liver disease. Semin. Liver Dis. 6, 221-232 (1986). (Pubitemid 17203551)
64. Svegliati-Baroni, G., Baraona, E., Rosman, A. S. & Lieber, C. S. Collagen-acetaldehyde adducts in alcoholic and nonalcoholicliver diseases. Hepatology 20, 111-118 (1994). (Pubitemid 24196499)
65. You, M. & Crabb, D. W. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G1-G6 (2004). (Pubitemid 38802112)
66. Zhou, Z., Sun, X. & Kang, Y. J. Ethanol-induced apoptosis in mouse liver: Fas- and cytochrome c-mediated caspase-3 activation pathway. Am. J. Pathol. 159, 329-338 (2001). (Pubitemid 33704218)
67. Bradham, C. A., Plümpe, J., Manns, M. P., Brenner, D. A. & Trautwein, C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am. J. Physiol. 275, G387-G392 (1998).
68. Romαn, J. et al. Differential role of ethanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: effect on transcription factors AP-1 and NF-kB. Hepatology 30, 1473-1480 (1999).
69. Meagher, E. A. et al. Alcohol-induced generation of lipid peroxidation products in humans. J. Clin. Invest. 104, 805-813 (1999). (Pubitemid 29536366)
70. Bailey, S. M. & Cunningham, C. C. Acute and chronic ethanol increases reactive oxygen species generation and decreases viability in fresh, isolated rat hepatocytes. Hepatology 28, 1318-1328 (1998).
71. Mansouri, A. et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 117, 181-190 (1999). (Pubitemid 29297636)
72. Ji, C. & Kaplowitz, N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 124, 1488-1499 (2003). (Pubitemid 36531821)
73. Yin, M. et al. Alcohol-induced free radicals in mice: direct toxicants or signaling molecules? Hepatology 34, 935-942 (2001). (Pubitemid 33032028)
74. Bird, G. L., Sheron, N., Goka, A. K., Alexander, G. J. & Williams, R. S. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann. Intern. Med. 112, 917-920 (1990). (Pubitemid 20193676)
75. Dominguez, M. et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 136, 1639-1650 (2009).
76. Colmenero, J. et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 132, 687-697 (2007). (Pubitemid 46274670)
77. Morales, O. et al. Osteopontin is a novel therapeutic target in patients with alcoholic hepatitis. J. Hepatol. 52 (Suppl. 1), S23 (2010).
78. Horiguchi, N. et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 134, 1148-1158 (2008). (Pubitemid 351451970)
79. Ki, S. H. et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 52, 1291-1300 (2010).
80. Lemmers, A. et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49, 646-657 (2009).
81. Yin, M. et al. Reduced early alcohol-induced liver injury in CD14-deficient mice. J. Immunol. 166, 4737-4742 (2001). (Pubitemid 32233762)
82. Donohue, T. M. Jr, Cederbaum, A. I. & French, S. W. Role of the proteasome in ethanol-induced liver pathology. Alcohol. Clin. Exp. Res. 31, 1446-1459 (2007). (Pubitemid 47319662)
83. Yip, W. W. & Burt, A. D. Alcoholic liver disease. Semin. Diagn. Pathol. 23, 149-160 (2006). (Pubitemid 46176510)
84. Friedman, S. L. Stellate cell activation in alcoholic fibrosis-an overview. Alcohol. Clin. Exp. Res. 23, 904-910 (1999). (Pubitemid 29256580)
85. Wang, J. H., Batey, R. G. & George, J. Role of ethanol in the regulation of hepatic stellate cell function. World J. Gastroenterol. 12, 6926-6932 (2006). (Pubitemid 44834881)
86. Moreno, M. & Bataller, R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin. Liver Dis. 12, 825-852 (2008).
87. Naveau, S. et al. Serum leptin in patients with alcoholic liver disease. Alcohol. Clin. Exp. Res. 30, 1422-1428 (2006). (Pubitemid 44114694)
88. Kluwe, J. et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138, 347-359 (2010).
89. Houstis, N., Rosen, E. D. & Lander, E. S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440, 944-948 (2006).
90. Lieber, C. S. et al. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol. Clin. Exp. Res. 32, 1031-1039 (2008). (Pubitemid 351733086)
91. Arthur, M. J., Iredale, J. P. & Mann, D. A. Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease. Alcohol. Clin. Exp. Res. 23, 940-943 (1999). (Pubitemid 29256587)
92. Zhu, L. et al. Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS ONE 6, e17415 (2011).
93. Weber, S. N. & Lammert, F. Genetics of liver injury and fibrosis. Alcohol. Clin. Exp. Res. 35, 800-803 (2011).
94. Wilfred de Alwis, N. M. & Day, C. P. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin. Liver Dis. 27, 44-54 (2007).
95. Altamirano, J. & Bataller, R. Cigarette smoking and chronic liver diseases. Gut 59, 1159-1162 (2010).
96. Stepanova, M., Rafiq, N. & Younossi, Z. M. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 59, 1410-1415 (2010).
97. Hrubec, Z. & Omenn, G. S. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol. Clin. Exp. Res. 5, 207-215 (1981). (Pubitemid 11116962)
98. Bataller, R., North, K. E. & Brenner, D. A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37, 493-503 (2003). (Pubitemid 36258768)
99. Day, C. P. et al. Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage. Hepatology 14, 798-801 (1991).
100. Zintzaras, E., Stefanidis, I., Santos, M. & Vidal, F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 43, 352-361 (2006).
101. Jarvelainen, H. A. et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 33, 1148-1153 (2001). (Pubitemid 32378214)
102. Stickel, F. et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 53, 86-95 (2011).
103. Trépo, E. et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J. Hepatol. doi:10.1016/j.jhep.2011.01.028.
104. Bird, G. L. et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann. Intern. Med. 112, 917-920 (1990). (Pubitemid 20193676)
105. Domínguez, M. et al. Functional analysis of hepatic gene expression profiling from patients with alcoholic hepatitis reveals new targets for therapy. J. Hepatol. 50 (Suppl. 1), S39 (2009).
106. Horiguchi, N. et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 134, 1148-1158 (2008). (Pubitemid 351451970)
107. Domínguez, M. et al. Identification of Fn14, a TNF receptor superfamily member, as a therapeutic target in patients with alcoholic hepatitis. Hepatology 50 (Suppl. 4), 609A (2009).
108. Ribeiro, P. S. et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 99, 1708-1717 (2004). (Pubitemid 39237497)
109. Ramalho, R. M. et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur. J. Gastroenterol. Hepatol. 18, 21-29 (2006). (Pubitemid 43004877)
110. Kalaitzakis, E., Gunnarsdottir, S. A., Josefsson, A. & Björnsson, E. Increased risk for malignant neoplasms among patients with cirrhosis. Clin. Gastroenterol. Hepatol. 9, 168-174 (2011).
111. Ishikawa, M. et al. Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia. Alcohol. Clin. Exp. Res. 34 (Suppl. 1), S25-S33 (2010).
112. Matsuyama, T. et al. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol. Clin. Exp. Res. 31 (Suppl. 1), S27-S35 (2007).
113. Mookerjee, R. P. et al. Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis. Gastroenterology 132, 2533-2541 (2007). (Pubitemid 46890854)
114. Bor, S. et al. Effect of ethanol on the structure and function of rabbit esophageal epithelium. Am. J. Physiol. 274, G819-G826 (1998).
115. Bor, S., Bor-Caymaz, C., Tobey, N. A., Abdulnour-Nakhoul, S. & Orlando, R. C. Esophageal exposure to ethanol increases risk of acid damage in rabbit esophagus. Dig. Dis. Sci. 44, 290-300 (1999). (Pubitemid 29093552)
116. Salo, J. A. Ethanol-induced mucosal injury in rabbit oesophagus. Scand. J. Gastroenterol. 18, 713-721 (1983). (Pubitemid 13005016)
117. Yamada, Y., Weller, R. O., Kleihues P & Ludeke, B. I. Effects of ethanol and various alcoholic beverages on the formation of O6- methyldeoxyguanosine from concurrently administered N-nitrosomethylbenzylamine in rats: a dose-response study. Carcinogenesis 13, 1171-1175 (1992).
118. Tsukamoto, H., Towner, S. J., Yu, G. S. & French, S. W. Potentiation of ethanol-induced pancreatic injury by dietary fat. Induction of chronic pancreatitis by alcohol in rats. Am. J. Pathol. 131, 246-257 (1988).
119. Tsukamoto, H., Reidelberger, R. D., French, S. W. & Largman, C. Long-term cannulation model for blood sampling and intragastric infusion in the rat. Am. J. Physiol. 247, R595-R599 (1984). (Pubitemid 14003652)
120. Ciccocioppo, R. et al. Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. Addict. Biol. 11, 339-355 (2006). (Pubitemid 46696907)
121. Tsukamoto, H. et al. Severe and progressive steatosis and focal necrosis in rat liver induced by continuous intragastric infusion of ethanol and low fat diet. Hepatology 5, 224-232 (1985). (Pubitemid 15115999)
122. French, S. W. Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease. J. Biomed. Sci. 8, 20-27 (2001). (Pubitemid 32098482)
123. Lieber, C. S. & DeCarli, L. M. An experimental model of alcohol feeding and liver injury in the baboon. J. Med. Primatol. 3, 153-163 (1974).
124. Lieber, C. S., Jones, D. P. & DeCarli, L. M. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J. Clin. Invest. 44, 1009-1021 (1965).
125. Lieber, C. S., DeCarli, L. & Rubin, E. Sequential production of fatty liver, hepatitis, and cirrhosis in sub-human primates fed ethanol with adequate diets, Proc. Natl Acad. Sci. USA 72, 437-441 (1975).
126. Niemelä, O. et al. Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology 22, 1208-1214 (1995).
127. Halsted, C. H. et al. Centrilobular distribution of acetaldehyde and collagen in the ethanol-fed micropig. Hepatology 18, 954-960 (1993).
128. Järveläinen, H. A., Fang, C., Ingelman-Sundberg, M. & Lindros K. O. Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. Hepatology 29, 1503-1510 (1999). (Pubitemid 29211053)
129. Bode, C., Gast, J., Zelder, O., Jerusalem, C. R. & Bode, J. C. Alcohol-induced liver injuries after jejunoileal bypass operation in rats. J. Hepatol. 5, 75-84 (1987). (Pubitemid 17119080)
130. Zhang, H. Y. et al. Multiple pathogenic factor-induced complications of cirrhosis in rats: a new model of hepatopulmonary syndrome with intestinal endotoxemia. World J. Gastroenterol. 13, 3500-3507 (2007).
131. Yin, M. et al. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology 117, 942-952 (1999). (Pubitemid 29468238)
132. Kono, H. et al. CYP2E1 is not involved in early alcohol-induced liver injury. Am. J. Physiol. 277, G1259-G1267 (1999). (Pubitemid 30046029)
133. Kono, H. et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J. Clin. Invest. 106, 867-872 (2000).
134. Tsukamoto, H. et al. Experimental liver cirrhosis induced by alcohol and iron. J. Clin. Invest. 96, 620-630 (1995).
135. Crabb, D. W., Galli, A., Fischer, M. & You, M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor α. Alcohol 34, 35-38 (2004).
136. Miller, A. M. et al. Inflammation-associated IL-6/STAT3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in IL-10 deficient mice. Hepatology doi:10.1002/hep.24517.
137. Kono, H. et al. ICAM-1 is involved in the mechanism of alcohol-induced liver injury: studies with knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G1289-G1295 (2001).
138. You, M., Matsumoto, M., Pacold, C. M., Cho, W. K. & Crabb, D. W. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127, 1798-1808 (2004). (Pubitemid 39575858)
139. Lamlé, J. et al. Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 134, 1159-1168 (2008).
140. Morgan, K., French, S. W. & Morgan, T. R. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 36, 122-134 (2002). (Pubitemid 34700769)
141. Stärkel, P., De Saeger, C., Strain, A. J., Leclercq, I. & Horsmans, Y. NFkB, cytokines, TLR 3 and 7 expression in human end-stage HCV and alcoholic liver disease. Eur. J. Clin. Invest. 40, 575-584 (2010).
142. Lemmers, A. et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49, 646-657 (2009).
143. Morales-Ibanez, O. et al. Proteomic analysis identifies P90RSK as a novel therapeutic target in patients with alcoholic hepatitis. J. Hepatol. 54 (Suppl. 1), S9 (2011).
144. Mookerjee, R. P. et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 45, 62-71 (2007). (Pubitemid 46144365)
145. Lluch, P. et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J. Hepatol. 41, 55-59 (2004). (Pubitemid 39005153)
146. Naveau, S. et al. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease. J. Hepatol. 52, 895-902 (2010).